國家衛生研究院 NHRI:Item 3990099045/13011

NHRI > National Institute of Infectious Diseases and Vaccinology > Shu-Chen Kuo > Periodical Articles > Item 3990099045/13011

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13011

Title:	Clinical and molecular characterization of Acinetobacter seifertii in Taiwan
Authors:	Li, LH;Yang, YS;Sun, JR;Huang, TW;Huang, WC;Chen, FJ;Wang, YC;Kuo, TH;Kuo, SC;Chen, TL;Lee, YT;ACTION study group
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	OBJECTIVES: Acinetobacter seifertii, a new member of the Acinetobacter baumannii group, has emerged as a cause of severe infections in humans. We investigated the clinical and molecular characteristics of A. seifertii. PATIENTS AND METHODS: This retrospective study enrolled 80 adults with A. seifertii bloodstream infection (BSI) at four medical centres over an 8 year period. Species identification was confirmed by MALDI-TOF MS, rpoB sequencing and WGS. Molecular typing was performed by MLST. Clinical information, antimicrobial susceptibility and the mechanisms of carbapenem and colistin resistance were analysed. Transmissibility of the carbapenem-resistance determinants was examined by conjugation experiments. RESULTS: The main source of A. seifertii BSI was the respiratory tract (46.3%). The 28 day and in-hospital mortality rates of A. seifertii BSI were 18.8% and 30.0%, respectively. High APACHE II scores and immunosuppressant therapy were independent risk factors for 28 day mortality. The most common MLST type was ST553 (58.8%). Most A. seifertii isolates were susceptible to levofloxacin (86.2%), and only 37.5% were susceptible to colistin. Carbapenem resistance was observed in 16.3% of isolates, mostly caused by the plasmid-borne ISAba1-blaOXA-51-like genetic structure. A. seifertii could transfer various carbapenem-resistance determinants to A. baumannii, Acinetobacter nosocomialis and other A. seifertii isolates. Variations of pmrCAB and lpxCAD genes were not associated with colistin resistance of A. seifertii. CONCLUSIONS: Levofloxacin and carbapenems, but not colistin, have the potential to be the drug of choice for A. seifertii infections. A. seifertii can transfer carbapenem-resistance determinants to other species of the A. baumannii group and warrants close monitoring.
Date:	2021-02
Relation:	Journal of Antimicrobial Chemotherapy. 2021 Feb;76(2):312-321.
Link to:	http://dx.doi.org/10.1093/jac/dkaa432
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0305-7453&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000620813200006
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85100279976
Appears in Collections:	[Shu-Chen Kuo] Periodical Articles [Feng-Jui Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB33128052.pdf		580Kb	Adobe PDF	312	View/Open

Loading...